Ferry Ossendorp studied Biology and obtained his PhD degree in 1989 at the Netherlands Cancer Institute, University of Amsterdam. Postdoctoral research was carried out in the Immunology Division at the Netherlands Cancer Institute till 1992. Since 1993 started as a senior scientist in the department of Immunohematology and Blood transfusion in LUMC. Since 1996 he is scientific staff member of the department and group leader. He became Associate Professor in 2005 and Full Professor in 2010. From 2013-2019 he was Scientific board member of Dutch Cancer Foundation KWF. Ferry Ossendorp has currently published 172 peer-reviewed publications and is inventor on five patents involving potentiation of cancer vaccines.
Autophagy regulates long-term cross-presentation by murine dendritic cells.
Ho NI, Camps MGM, Verdoes M, Münz C, Ossendorp F.
Eur J Immunol. 2020 Dec 22. doi: 10.1002/eji.202048961
Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer.
Hos BJ, Camps MGM, van den Bulk J, Tondini E, van den Ende TC, Ruano D, Franken K, Janssen GMC, Ru A, Filippov DV, Arens R, van Veelen PA, Miranda N, Ossendorp F.
Oncoimmunology. 2019 Oct 13;9(1):1673125
PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors.
Beyrend G, van der Gracht E, Yilmaz A, van Duikeren S, Camps M, Höllt T, Vilanova A, van Unen V, Koning F, de Miranda NFCC, Arens R, Ossendorp F.
J Immunother Cancer. 2019 Aug 14;7(1):217